ACRV logo

Acrivon Therapeutics, Inc.NasdaqGM:ACRV Stock Report

Market Cap US$42.5m
Share Price
US$1.35
My Fair Value
US$11
87.9% undervalued intrinsic discount
1Y-83.8%
7D9.8%
Portfolio Value
​
View

Acrivon Therapeutics, Inc.

NasdaqGM:ACRV Stock Report

Market Cap: US$42.5m

Acrivon Therapeutics (ACRV) Stock Overview

A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. More details

ACRV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 72.51% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 8.6% per year for the next 3 years

Does not have a meaningful market cap ($42M)

Currently unprofitable and not forecast to become profitable over the next 3 years


ACRV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Acrivon Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Acrivon Therapeutics
Historical stock prices
Current Share PriceUS$1.35
52 Week HighUS$10.16
52 Week LowUS$1.05
Beta1.67
1 Month Change0%
3 Month Change8.00%
1 Year Change-83.79%
3 Year Changen/a
5 Year Changen/a
Change since IPO-91.89%

Recent News & Updates

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Aug 15
Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Mar 27
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Recent updates

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Aug 15
Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Mar 27
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Dec 12

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Nov 17
We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 18

Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

Jul 17
Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Mar 29
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Oct 05
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Jun 22
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Feb 22
We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Shareholder Returns

ACRVUS BiotechsUS Market
7D9.8%4.7%1.3%
1Y-83.8%-6.9%16.1%

Return vs Industry: ACRV underperformed the US Biotechs industry which returned -6.9% over the past year.

Return vs Market: ACRV underperformed the US Market which returned 16.1% over the past year.

Price Volatility

Is ACRV's price volatile compared to industry and market?
ACRV volatility
ACRV Average Weekly Movement8.6%
Biotechs Industry Average Movement10.8%
Market Average Movement6.4%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: ACRV has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ACRV's weekly volatility has decreased from 15% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201877Peter Blume-Jensenacrivon.com

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer.

Acrivon Therapeutics, Inc. Fundamentals Summary

How do Acrivon Therapeutics's earnings and revenue compare to its market cap?
ACRV fundamental statistics
Market capUS$42.47m
Earnings (TTM)-US$85.96m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.5x
P/E Ratio

Is ACRV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACRV income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$85.96m
Earnings-US$85.96m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.73
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ACRV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/18 15:18
End of Day Share Price 2025/08/15 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrivon Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Li Wang WatsekCantor Fitzgerald & Co.
Silvan TuerkcanCitizens JMP Securities, LLC
Emily BodnarH.C. Wainwright & Co.